New diabetes drug studied in kidney patients

NCT ID NCT07385547

Recruiting now Knowledge-focused Sponsor: Sun Pharmaceutical Industries Limited Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage study tests how a single dose of the diabetes drug GL0034 behaves in people with different levels of kidney function. About 40 adults with type 2 diabetes will be grouped by kidney health, from normal to severe impairment. Researchers will measure drug levels in the blood and check for side effects to guide future dosing.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: GL0034 (a long-acting GLP-1 receptor agonist)
What this could lead to: If successful, this study could help doctors decide safe dosing of GL0034 for people with type 2 diabetes who also have kidney problems.
What could go wrong: This is a very early Phase 1 study with only 40 people. It only looks at drug levels and safety after one dose, not long-term effects or effectiveness.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RENAL IMPAIRMENT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

impaired renal function disease type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

TYPE II DIABETES MELLITUS

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

Orlando Clinical Research Center (OCRC)
NOT_YET_RECRUITING

Orlando, Florida, 32809, United States
Panax Clinical Research
RECRUITING

Miami Lakes, Florida, 33014, United States
Syneos Miami
NOT_YET_RECRUITING

Miami, Florida, 33136, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.